Fmr LLC trimmed its holdings in shares of Catalent Inc (NYSE:CTLT) by 4.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,603,648 shares of the company’s stock after selling 178,145 shares during the quarter. Fmr LLC owned 2.48% of Catalent worth $164,147,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in CTLT. Nelson Van Denburg & Campbell Wealth Management Group LLC purchased a new stake in shares of Catalent during the second quarter worth about $145,000. Moneta Group Investment Advisors LLC increased its position in shares of Catalent by 105.0% during the second quarter. Moneta Group Investment Advisors LLC now owns 3,515 shares of the company’s stock worth $147,000 after acquiring an additional 1,800 shares during the last quarter. CIBC Asset Management Inc purchased a new stake in shares of Catalent during the third quarter worth about $217,000. Rehmann Capital Advisory Group increased its position in shares of Catalent by 1,895.9% during the second quarter. Rehmann Capital Advisory Group now owns 5,309 shares of the company’s stock worth $222,000 after acquiring an additional 5,043 shares during the last quarter. Finally, Chicago Equity Partners LLC purchased a new stake in shares of Catalent during the third quarter worth about $237,000. 96.77% of the stock is currently owned by institutional investors and hedge funds.
NYSE:CTLT opened at $36.32 on Friday. The stock has a market capitalization of $5.53 billion, a P/E ratio of 22.84, a PEG ratio of 2.38 and a beta of 1.44. Catalent Inc has a one year low of $34.24 and a one year high of $47.87. The company has a debt-to-equity ratio of 1.44, a current ratio of 2.05 and a quick ratio of 1.61.
Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, November 6th. The company reported $0.28 EPS for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.04. The business had revenue of $551.80 million during the quarter, compared to the consensus estimate of $582.44 million. Catalent had a return on equity of 19.13% and a net margin of 2.65%. The company’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period last year, the firm earned $0.21 earnings per share. On average, analysts predict that Catalent Inc will post 1.63 EPS for the current year.
In related news, Director John J. Greisch bought 13,000 shares of the firm’s stock in a transaction on Thursday, November 8th. The stock was bought at an average cost of $37.61 per share, for a total transaction of $488,930.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John R. Chiminski sold 130,545 shares of Catalent stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $45.32, for a total value of $5,916,299.40. The disclosure for this sale can be found here. Insiders sold 184,335 shares of company stock valued at $8,161,727 over the last quarter. Insiders own 1.40% of the company’s stock.
CTLT has been the subject of a number of research reports. Zacks Investment Research downgraded Catalent from a “hold” rating to a “sell” rating in a research note on Monday, September 3rd. Royal Bank of Canada set a $45.00 price target on Catalent and gave the stock a “buy” rating in a research note on Friday, November 16th. First Analysis upgraded Catalent from a “neutral” rating to an “outperform” rating and decreased their price target for the stock from $47.00 to $43.00 in a research note on Wednesday, November 7th. ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a research note on Monday, November 12th. Finally, UBS Group initiated coverage on Catalent in a research note on Tuesday, October 9th. They issued a “neutral” rating and a $48.00 price target for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. Catalent currently has an average rating of “Buy” and an average price target of $48.00.
ILLEGAL ACTIVITY NOTICE: “Fmr LLC Has $164.15 Million Stake in Catalent Inc (CTLT)” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/12/08/fmr-llc-has-164-15-million-stake-in-catalent-inc-ctlt.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
See Also: Understanding Market Liquidity
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.